133 STAT. 950  PUBLIC LAW 116–22—JUNE 24, 2019  TITLE V—INCREASING COMMUNICA- TION IN MEDICAL COUNTERMEASURE  ADVANCED RESEARCH AND DEVELOP- MENT  SEC. 501. MEDICAL COUNTERMEASURE BUDGET PLAN.  SEC. 502. MATERIAL THREAT AND MEDICAL COUNTERMEASURE  NOTIFICATIONS.  Determinations.  Deadline.  (a) CONGRESSIONAL NOTIFICATION OF MATERIAL THREAT DETER- MINATION.—Section 319F–2(c)(2)(C) (42 U.S.C. 247d–6b(c)(2)(C)) is  amended by striking ‘‘The Secretary and the Homeland Security  Secretary shall promptly notify the appropriate committees of Con- gress’’ and inserting ‘‘The Secretary and the Secretary of Homeland  Security shall send to Congress, on an annual basis, all current  material threat determinations and shall promptly notify the Com- mittee on Health, Education, Labor, and Pensions and the Com- mittee on Homeland Security and Governmental Affairs of the  Senate and the Committee on Energy and Commerce and the Com- mittee on Homeland Security of the House of Representatives’’.  (b) CONTRACTING COMMUNICATION.—Section 319F– 2(c)(7)(B)(ii)(III) (42 U.S.C. 247d–6b(c)(7)(B)(ii)(III)) is amended by  adding at the end the following: ‘‘The Secretary shall notify the  Section 2811(b)(7) (42 U.S.C. 300hh–10(b)(7)) is amended—  (1) in the matter preceding subparagraph (A), by striking  ‘‘March 1’’ and inserting ‘‘March 15’’;  (2) in subparagraph (A)—  (A) in clause (ii), by striking ‘‘; and’’ and inserting  ‘‘;’’; and  (B) by striking clause (iii) and inserting the following:  ‘‘(iii) procurement, stockpiling, maintenance, and  potential replenishment (including manufacturing  capabilities) of all products in the Strategic National  Stockpile;  ‘‘(iv) the availability of technologies that may assist  in the advanced research and development of counter- measures and opportunities to use such technologies  to accelerate and navigate challenges unique to  countermeasure research and development; and  ‘‘(v) potential deployment, distribution, and utiliza- tion of medical countermeasures; development of clin- ical guidance and emergency use instructions for the  use of medical countermeasures; and, as applicable,  potential postdeployment activities related to medical  countermeasures;’’;  (3) by redesignating subparagraphs (D) and (E) as subpara- graphs (E) and (F), respectively; and  (4) by inserting after subparagraph (C), the following:  ‘‘(D) identify the full range of anticipated medical  countermeasure needs related to research and development,  procurement, and stockpiling, including the potential need  for indications, dosing, and administration technologies,  and other countermeasure needs as applicable and appro- priate;’’. 